Health Media ArticlesExcerpts of Key Health Media Articles in Major Media
Below are key excerpts of revealing news articles on health from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.
For further exploration, delve into our comprehensive Health and Food Corruption Information Center.
Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
A new breed of lifestyle drugs could allow us to choose how much we sleep, boost our memories and even allow us to enjoy ourselves more, without any side effects. Will they unleash human capabilities never seen before or create a dystopian 24-hour society where we are dependent on drugs to regulate our lifestyle and behavior? One drug already available is modafinil, marketed as the vaguely Orwellian-sounding Provigil. It enables those who take it to stay awake and alert for 48 hours. It is a eugeroic that delivers a feeling of wakefulness without the physical or mental jitter. There is already a market for it for those without any medical need - it is developing a cult following among workaholics and students studying for exams. The military is also very interested in eugeroic. Their reliance on amphetamines for lengthy operations have had catastrophic consequences in the past. The "friendly-fire" incidents in Afghanistan in 2002 when U.S. pilots killed Canadian troops was blamed on the "go pills" they had taken. The U.S. Defense Advanced Research Projects Agency (DARPA) tested a compound called CX717 in its quest to find a drug that can create a "metabolically dominant war-fighter of the future" able to function for seven days without sleep. CX717 is an ampakine, a compound that increases the brains computing powers. It re-writes the rules of what it takes to create a memory and just how strong those memories can be. Will cans of soda containing eugeroics or ampakines be as common as caffeine drinks on the shelves of 24-hour stores? The potential is certainly there for a brave new world of personality medication.
There are no magic bullets in the fight against cancer: that's the first thing every responsible scientist mentions when discussing a possible new treatment, no matter how promising. If there were a magic bullet, though, it might be something like dichloroacetate, or DCA, a drug that kills cancer cells by exploiting a fundamental weakness found in a wide range of solid tumors. So far, though, it kills them just in test tubes and in rats infected with human cancer cells; it has never been tested against cancer in living human beings. DCA ... is an existing drug whose side effects are well-studied and relatively tolerable. Also, it's a small molecule that might be able to cross the blood-brain barrier to reach otherwise intractable brain tumors. Within days after a technical paper on DCA appeared in the journal Cancer Cell last week, the lead author, Dr. Evangelos Michelakis of the University of Alberta, was deluged with calls and e-mails from prospective patients—to whom he can say only, “Hang in there.” DCA is a remarkably simple molecule. It acts in the body to promote the activity of the mitochondria. Researchers have assumed that the mitochondria in cancer cells were irreparably damaged. But Michelakis wondered if that was really true. With his colleagues he used DCA to turn back on the mitochondria in cancer cells—which promptly died. One of the great things about DCA is that it's a simple compound, in the public domain, and could be produced for pennies a dose. But that's also a problem, because big drug companies are unlikely to spend a billion dollars or so on large-scale clinical trials for a compound they can't patent.
Note: Read a 2010 follow-up by Dr. Michelakis with promising results and watch a 10-minute video. Explore the DCA website. Why didn't other mass media report this major story? Why aren't many millions of dollars being poured into research? Notice even Newsweek acknowledges the drug companies are not interested in finding a cure for cancer if they can't make a profit from it. Some suspect the drug companies have even suppressed cancer cures found in the past. See one amazing example of this. For more, see these major media articles on potential cancer cures.
Dr. Brooke Herndon, an internist at Dartmouth-Hitchcock Medical Center, could not stop coughing. Dr. Kathryn Kirkland, an infectious disease specialist at Dartmouth, had a chilling thought: Could she be seeing the start of a whooping cough epidemic? By late April, other health care workers at the hospital were coughing. It was the start of a bizarre episode at the medical center: the story of the epidemic that wasn’t. For months, nearly everyone involved thought the medical center had had a huge whooping cough outbreak, with extensive ramifications. Nearly 1,000 health care workers ... were given a preliminary test and furloughed from work until their results were in; 142 people, including Dr. Herndon, were told they appeared to have the disease; and thousands were given antibiotics and a vaccine for protection. The whole thing was a false alarm. Now, as they look back on the episode, epidemiologists and infectious disease specialists say the problem was that they placed too much faith in a quick and highly sensitive molecular test that led them astray. Such tests are coming into increasing use and may be the only way to get a quick answer in diagnosing diseases like whooping cough, Legionnaire’s, bird flu, tuberculosis and SARS. There are no good estimates of their error rates. But their very sensitivity makes false positives likely, and when hundreds or thousands of people are tested, as occurred at Dartmouth, false positives can make it seem like there is an epidemic.
Note: For more along these lines, see concise summaries of deeply revealing news articles on health from reliable major media sources.
The two sides in the debate over genetically modified crops issued warring reports assessing the first decade of the technology this week, as the industry's sunny view clashed with the darker vision of critics. The world's farmland planted with biotechnology crops reached 252 million acres in 2006, the industry-backed International Service for the Acquisition of Agri-Biotech Applications calculated in a report ... that promotes the products as solutions for hunger and future fuel demand. The report concluded that biotechnology boosts crop yields and benefits the environment. That view was challenged by Friends of the Earth International and the Center for Food Safety in a report released Wednesday. The two groups argued that engineered plants don't produce larger harvests than conventional varieties, are often more vulnerable to drought and have increased the use of pesticides. The United States and Argentina host about 70 percent of the world's biotech crop acreage, both sides said. But adoption of the technology is growing at a faster rate in developing countries than in industrialized nations, according to the International Service. About 10 million farmers in 22 countries sow genetically modified crops, it said. The dominant biotech crop is soybeans, with 57 percent of world acreage, followed by maize, cotton and canola. Opponents said the crops are mainly a boon to agribusiness and big agricultural chemical companies trying to increase sales of seeds, weed-killers and bug sprays. Biotech crop seeds are often engineered to be resistant to the herbicides or pesticides sold by the same company.
Note: For reliable information showing that you may be eating genetically modified food every day which scientific experiments have repeatedly demonstrated can cause sickness and even death, click here.
Data supplied by tobacco companies strongly suggest that in recent years manufacturers deliberately boosted nicotine levels in cigarettes to more effectively hook smokers, Harvard researchers conclude in a study being released today. The companies increasingly used tobacco richer in nicotine and made design changes to give smokers more puffs per cigarette, according to the analysis from the Harvard School of Public Health. The report expands on a landmark Massachusetts Department of Public Health study issued last August showing that the amount of nicotine that could be inhaled from cigarettes increased an average of 10 percent from 1998 through 2004. A 1996 state law required cigarette makers to test the nicotine that could be inhaled from their products, and the state ordered the use of machines that simulate a typical smoker's puffing. The Harvard researchers, who corroborated the basic findings of the state study, wanted to determine why cigarettes were delivering more nicotine. "Industry says it's changed," said Greg Connolly, an author of the Harvard study. "They've changed -- maybe for the worse." The Harvard study relies on information supplied by the industry. "It was systematic, it was pervasive, it involved all the manufacturers, and it was by design," said Dr. Howard Koh, an associate dean at the Harvard School of Public Health and an author of the study. Another author said that the likelihood that the nicotine increase happened by chance was less than 1 in 1,000.
In results that "astounded" scientists, an inexpensive molecule known as DCA was shown to shrink lung, breast and brain tumours in both animal and human tissue experiments. The study was published yesterday in the journal Cancer Cell. "I think DCA can be selective for cancer because it attacks a fundamental process of cancer that is unique to cancer cells," said Dr. Evangelos Michelakis, a professor at the Edmonton university's medical school and one of the study's key authors. The molecule appears to repair damaged mitochondria in cancer cells. "When a cell is getting too old or doesn't function properly, the mitochondria are going to induce the cell death," lead study author Sebastien Bonnet said yesterday. Bonnet says DCA – or dichloroacetate – appears to reverse the mitochondrial changes in a wide range of cancers. "One of the really exciting things about this compound is that it might be able to treat many different forms of cancer because all forms of cancer suppress mitochondrial function," Michelakis said. Bonnet says DCA may also provide an effective cancer treatment because its small size allows easy absorption into the body, ensuring it can reach areas that other drugs cannot, such as brain tumours. Because it's been used to combat other ailments ... DCA has been shown to have few toxic effects on the body. Its previous use means it can be immediately tested on humans. Unlike other cancer drugs, DCA did not appear to have any negative effect on normal cells. It could provide an extremely inexpensive cancer therapy because it's not patented. But ... the lack of a patent could lead to an unwillingness on the part of pharmaceutical companies to fund expensive clinical trials.
Note: Even these scientists realize that though this discovery could be a huge benefit to mankind, because the drug companies will lose profits, they almost certainly will not fund studies. Expensive AIDS drugs with promising results, on the other hand, are rushed through the studies to market. For more reliable, verifiable information on how hugely beneficial health advances are shut down to keep profits high, click here and here.
A team at the institute that cloned Dolly the sheep have made a genetically engineered chicken that produces cancer drugs in its eggs. The chickens produce the cancer drugs in their egg whites, the team at the Roslin Biocentre in Edinburgh reported. The drugs include a monoclonal antibody — themselves lab-engineered immune system proteins — and a human immune system protein used to treat cancer and other conditions. Scientists have been trying to find good ways to turn animals into factories. Cattle, sheep and goats all have been genetically engineered to produce human proteins in their milk, including insulin and drugs to treat cystic fibrosis, but the Roslin team thought chickens, with their shorter life cycles and egg-laying prowess, also might be useful. They used a virus to infect very early chicken embryos. The virus inserted the genetic material into the DNA of chick embryos in newly laid eggs. The researchers hatched these chicks and found the male chicks who had indeed incorporated the new DNA in their semen. These cockerels were then bred with normal hens and they screened the resulting chicks to see which ones still carried the two new genes. The researchers have now bred several hundred chickens that can produce the desired proteins. Other companies have created animals and plants that produce human and animal proteins, as well as vaccines.
Note: It's a brave new world. For more on genetically modified organisms, click here.
Two UK-based academics have devised a way to invent new medicines and get them to market at a fraction of the cost charged by big drug companies. Sunil Shaunak, professor of infectious diseases at Imperial College ... calls their revolutionary new model "ethical pharmaceuticals". Improvements they devise to the molecular structure of an existing, expensive drug turn it technically into a new medicine which is no longer under a 20-year patent to a multinational drug company and can be made and sold cheaply. The process has the potential to undermine the monopoly of the big drug companies and bring cheaper drugs not only to poor countries but back to the UK. Professor Shaunak and his colleague from the London School of Pharmacy, Steve Brocchini, have linked up with an Indian biotech company which will manufacture the first drug - for hepatitis C. Hepatitis C affects 170 million people worldwide and at least 200,000 in the UK. Multinational drug companies put the cost of the research and development of a new drug at $800m (Ł408m). Professors Shaunak and Brocchini say the cost of theirs will be only a few million pounds. Professor Shaunak says it is time that the monopoly on drug invention and production by multinational corporations - which charge high prices because they need to make big profits for their shareholders - was broken. The team's work on the hepatitis C drug has impeccable establishment credentials. But the professors' ethical pharmaceutical model is unlikely to find much favour with the multinational pharmaceutical companies, which already employ large teams of lawyers to defend the patents which they describe as the lifeblood of the industry.
Note: This is very exciting news, but we'll see what happens when the hugely profitable pharmaceutical industry presses its might against this effort. For more, click here.
[Book Review of] Medical Apartheid: The Dark History of Medical Experimentation on Black Americans From Colonial Times to the Present. Harriet Washington opens the door on the torture room in "Medical Apartheid". Experimental operations on the skulls of slave children, Washington writes, were a favorite pursuit of a particularly sadistic South Carolinian doctor named J. Marion Sims, widely revered today as the "father of gynecology." For years, Sims experimented on a group of slave women, to whom he refused anesthesia. The most notorious post-slavery racial crime of American medicine [was] the Tuskegee Syphilis Study, conducted by the U.S. Public Health Service between 1932 and 1972. More than 100 black subjects ... were denied treatment, even and especially after the discovery of penicillin in 1943. The research required that they suffer and die, the more slowly the better. Tuskegee was hardly unique. The Rockefeller Institute ... conducted a study in 1910 that saw 470 black syphilitics injected with a deadly strain of malaria. Black Americans were also disproportionately used ... as subjects in government inquiries into the effects of radiation. Washington's chilling history ends with contemporary case studies. At the Incarnation Children's Center in New York, Columbia University doctors continue to administer experimental AIDS drugs to minority orphans, even after many develop painful and debilitating reactions. As for current clinical trials in Africa, Washington describes the continent as the new "laboratory for the West," where unsuspecting patients regularly receive experimental therapies that might never receive state sanction in the United States or Europe.
Note: For more reliable, verifiable information on major corruption in the health industry, click here. It's also interesting to not that no other major media chose to review this important book.
Consumer advocates and others have complained bitterly in recent years that the Food and Drug Administration has veered from its scientific roots. Later this week, the agency is expected to release a formal recommendation that milk and meat from cloned animals should be allowed on grocery store shelves. The long-awaited decision comes as polling data to be released this week show that the public continues to have little appetite for such food, with many people saying the FDA should keep it off the market. That raises the issue: Should decisions such as this one be based solely on science, or should officials take into account public sensitivities, which may be unscientific but are undeniably real? "There is more to this issue than just food safety," said Susan Ruland of the International Dairy Foods Association, which represents such major companies as Kraft Foods and Dannon. The organization's member companies are concerned that sales of U.S. dairy products could drop by 15 percent or more if the FDA allows the sale of meat and milk from clones. Relatively few cloned farm animals exist; there are an estimated 150 clones out of the nation's 9 million dairy cows. But biotechnology companies are gearing up to clone farmers' tastiest cattle and pigs and most productive dairy cows. In the University of Maryland survey, nearly half of those polled asserted that it was not yet possible to clone farm animals for food. For the most part, people don't know this is a reality yet.
The drug maker Eli Lilly has engaged in a decade-long effort to play down the health risks of Zyprexa, its best-selling medication for schizophrenia, according to hundreds of internal Lilly documents and e-mail messages among top company managers. The documents ... show that Lilly executives kept important information from doctors about Zyprexa’s links to obesity and its tendency to raise blood sugar — both known risk factors for diabetes. Lilly’s own published data, which it told its sales representatives to play down in conversations with doctors, has shown that 30 percent of patients taking Zyprexa gain 22 pounds or more after a year on the drug, and some patients have reported gaining 100 pounds or more. But Lilly was concerned that Zyprexa’s sales would be hurt if the company was more forthright about the fact that the drug might cause unmanageable weight gain or diabetes, according to the documents, which cover the period 1995 to 2004. Zyprexa has become by far Lilly’s best-selling product, with sales of $4.2 billion last year, when about two million people worldwide took the drug. Critics, including the American Diabetes Association, have argued that Zyprexa, introduced in 1996, is more likely to cause diabetes than other widely used schizophrenia drugs. As early as 1999, the documents show that Lilly worried that side effects from Zyprexa, whose chemical name is olanzapine, would hurt sales. “Olanzapine-associated weight gain and possible hyperglycemia is a major threat to the long-term success of this critically important molecule,” Dr. Alan Breier wrote in a November 1999 e-mail message to two-dozen Lilly employees.
Note: For lots more on corporate corruption from reliable sources, click here.
A Toronto-led team of researchers has discovered a trigger for Type 1 diabetes, a breakthrough that has long evaded scientists and could lead the way to preventing the disease. The team found that abnormal nerve endings in the insulin-producing cells of the pancreas initiated a chain of events that caused Type 1 diabetes in mice. When they removed the nerve cells, the mice did not develop the disorder. That means diabetes may be a disease of the nervous system, not just an autoimmune disease, said Dr. Hans Michael Dosch, a senior scientist at the Hospital for Sick Children and the study's main investigator. In a reversal of what they expected, the researchers also found injecting substance P — a chemical secreted by nerve cells — into mice whose islet cells were inflamed and on the way to being destroyed not only eliminated the inflammation but reversed it. "The blood glucose normalizes overnight and it stays low for weeks to months — this is with a single shot," Dosch said. "We now have 4-month-old mice that are non-diabetic that used to be diabetic" — a period equivalent to six to eight years in humans. Experts say the findings, reported yesterday in the journal Cell, will change the way scientists think about diabetes. "It really is a breakthrough for the diabetes community," said Pam Ohashi, a professor of immunology at the University of Toronto. Dosch has immediate plans to move his research from mice to humans. He is launching a clinical trial in January to figure out if patients who have a high risk of Type 1 diabetes have the same sensory nerve abnormalities. "If they do, then we have fantastic new therapeutic strategies," said Dosch, who is also a professor of pediatrics and immunology at U of T.
Note: The pharmaceutical industry makes huge profits from diabetics. Big profits have been known to prevent cures from making it to market. Click here for more. Let's hope this important research moves forward.
Some 10,000 US researchers have signed a statement protesting about political interference in the scientific process. The statement, which includes the backing of 52 Nobel Laureates, demands a restoration of scientific integrity in government policy. According to the American Union of Concerned Scientists, data is being misrepresented for political reasons. It claims scientists working for federal agencies have been asked to change data to fit policy initiatives. The Union has released an "A to Z" guide that ... documents dozens of recent allegations involving censorship and political interference in federal science. Campaigners say that in recent years the White House has been able to censor the work of agencies like the Environmental Protection Agency and the Food and Drug Administration because a Republican congress has been loath to stand up for scientific integrity. Michael Halpern from the UCS said the statement of objection to political interference had been supported by researchers regardless of their political views. "This science statement that has now been signed by the 10,000 scientists is signed by science advisers to both Republican and Democratic administrations dating back to President Eisenhower, stating that this is not business as usual and calling for this practice to stop."
Wireless networks — known as wi-fi or wLAN (wireless local area network) — are increasingly used in schools, offices and other public places to connect computers and laptops to the internet using radiofrequency transmitters with no need for complex cabling. In future, whole town centres will be transformed into wi-fi “hot spots.” It has taken the public a while to wake up to the idea that wireless transmitters could be less than benign. The groundswell of concern is mounting, with some people blaming everything from headaches to cancer on exposure to radio-frequency fields. A number of schools have dismantled their wireless networks after lobbying from worried parents, and others are under pressure to follow suit. In Austria the public health department of Salzburg has advised schools and kindergartens not to use wLAN or cordless phones. Lakehead University in Ontario, Canada, which has 7,400 students, has removed wi-fi because of what its Vice-Chancellor, Dr Fred Gilbert, calls “the weight of evidence demonstrating behavioural effects and physiological impacts at the tissue, cellular and cell level”. Some experts have also expressed concerns. In September, 30 scientists from all over the world signed a resolution calling for a “full and independent review of the scientific evidence that points to hazards from current electromagnetic field exposure conditions worldwide.”
Note: For many highly important articles from reliable sources on major health issues, click here.
One hundred years ago, companies were free to follow their own rules. The publication of Upton Sinclair’s novel “The Jungle” in 1906 — with its descriptions of rat-infested slaughterhouses and rancid meat — created public outrage over food safety. Even though the book was written by a socialist agitator, a Republican president, Theodore Roosevelt, eagerly read it. After confirming Sinclair’s claims, Roosevelt battled the drug companies, the big food processors and the meatpacking companies to protect American consumers from irresponsible corporate behavior. Over the past 40 years, the industrialization and centralization of our food system has greatly magnified the potential for big outbreaks. As a result, a little contamination can go a long way. The Taco Bell distribution center in New Jersey now being investigated as a possible source of E. coli supplies more than 1,100 restaurants in the Northeast. Since 2000, the fast-food and meatpacking industries have given about four-fifths of their political donations to Republican candidates for national office. In return, these industries have effectively been given control of the agencies created to regulate them. The current chief of staff at the Agriculture Department used to be the beef industry’s chief lobbyist. The person who headed the Food and Drug Administration until recently used to be an executive at the National Food Processors Association. Cutbacks in staff and budgets have reduced the number of food-safety inspections conducted by the F.D.A. to about 3,400 a year — from 35,000 in the 1970s.
Note: If you care about the health of our nation's food supply, write your political and media representatives encouraging the passage of the Safe Food Act mentioned in this article, which by the way, was written by the author of the most excellent book, Fast Food America.
The scientist who first linked smoking to lung cancer was [later] paid by a chemicals firm while investigating cancer risks in the industry. Professor Sir Richard Doll held a consultancy post with US firm Monsanto for more than 20 years. The BBC has seen private letters which show that Sir Richard ... received a US$1,500-a-day consultancy fee from Monsanto in the mid-1980s. During that time he investigated the potential cancer causing properties of the powerful herbicide Agent Orange, made by the company. Sir Richard [argued] that there was no evidence that Agent Orange caused cancer. Professor Lennart Hardell, of the Oncology Department at University Hospital Orebro, Sweden, has also studied the potential hazards posed by Agent Orange. He was one of the scientists whose work was dismissed by Sir Richard. He said: "It's quite OK to have contacts with industry, but you should be fair and say 'well, I'm [working] as a consultant for Monsanto." Further documents obtained by The Guardian newspaper allegedly show that Sir Richard was also paid a Ł15,000 fee by the Chemical Manufacturers Association, and chemicals companies Dow Chemicals and ICI for a review of vinyl chloride, used in plastics, which largely cleared the chemical of any link with cancers apart from liver cancer. Sir Richard's views on the chemical were used by the manufacturers' trade association to defend it for more than a decade.
Japan has again been forced to confront its wartime conduct after a former doctor in the country's imperial navy admitted he had conducted experiments on Filipino prisoners during the second world war. Akira Makino, 84, said in an interview with the Kyodo news agency that he had performed surgery and amputations on dozens of prisoners of war before they were executed in the Philippines. Mr Makino is one of several former Japanese soldiers who decided to reveal the truth about their country's use of human guinea pigs before they die. Unit 731, the imperial Japanese army's notorious germ warfare unit, killed thousands of Chinese civilians and Allied PoWs at its sprawling complex in Harbin, northern China. The victims ... were injected with typhus, cholera and other diseases. They died during the experiments or were executed to prevent them from talking about their experiences. As the end of the war approached, the unit destroyed evidence of their activities. The extent of their activities only came to light following testimony from repentant former doctors, soldiers and nurses. US authorities secretly granted unit officials immunity from prosecution in return for access to years of research into biological weapons. Several former Unit 731 officials went on to enjoy prominent careers in medicine, academia and business. Mr Makino ... said he remained haunted by memories of the experiments. "We should not repeat that misery again," he said. "I want to tell the truth about the war."
Note: Explore a list depicting the rampant use of humans as guinea pigs in government, military, and medical experiments over the last century.
The Department of Agriculture declared safe for human consumption yesterday an experimental variety of genetically engineered rice found to have contaminated the U.S. rice supply this summer. The move ... to deregulate the special long-grain rice, LL601, was seen as a legal boon to its creator, Bayer CropScience. The company applied for approval shortly after the widespread contamination was disclosed in August and now faces a class-action lawsuit filed by hundreds of farmers in Arkansas and Missouri. The experimental rice ... escaped from Bayer's test plots after the company dropped the project in 2001. The resulting contamination, once it became public, prompted countries around the world to block rice imports from the United States, sending rice futures plummeting and farmers into fits. In approving the rice, the USDA allowed Bayer to take a regulatory shortcut and skip many of the usual safety tests. Joseph Mendelson, legal director of the nonprofit Center for Food Safety, said the quick approval shows that the USDA is more concerned about the fortunes of the biotechnology industry than about consumers' health. "USDA is telling agricultural biotechnology companies that it doesn't matter if you're negligent, if you break the rules, if you contaminate the food supply with untested genetically engineered crops, we'll bail you out," Mendelson said in a statement. Officials in Europe, where genetically altered rice is derisively dubbed "Frankenfood," made clear as recently as last week that European countries will not accept any U.S. rice, he said.
Note: For reliable information on the deception and dangers of GM (Genetically Modified) food, click here.
Hoping to prevent Congress from letting the government negotiate lower drug prices for millions of older Americans on Medicare, the pharmaceutical companies have been recruiting Democratic lobbyists [and] lining up allies in the Bush administration and Congress. Many drug company lobbyists concede that the House is likely to pass a bill intended to drive down drug prices, but they are determined to block such legislation in the Senate. If that strategy fails, they are counting on President Bush to veto any bill that passes. With 49 Republicans in the Senate next year, the industry is confident that it can round up the 34 votes normally needed to uphold a veto. They began developing strategy last week at a meeting of the board of the Pharmaceutical Research and Manufacturers of America. Billy Tauzin, president of that group [and] a former congressman...met with Senator Byron L. Dorgan, a North Dakota Democrat who has been trying for six years to allow drug imports from Canada. The industry vehemently opposes such legislation. The 2003 Medicare law prohibits the federal government from negotiating drug prices or establishing a list of preferred drugs. Drug makers have not set a budget for their campaign. They and their trade groups already spend some $100 million a year on lobbying in Washington. Representative Frank Pallone Jr., Democrat of New Jersey [said] “The 2003 Medicare law was essentially written by the drug industry.” Drug companies may be open to some changes in the Medicare drug benefit, but they say they cannot accept any form of price negotiation.
Note: For lots of verifiable information on the power of the drug industry to corrupt Congress, click here.
Poor people are needlessly dying because drug companies and the governments of rich countries are blocking the developing world from obtaining affordable medicines. Five years to the day after the Doha declaration - a groundbreaking deal to give poor countries access to cheap drugs - was signed at the World Trade Organisation, Oxfam says things are worse. The charity accuses the US, which champions the interests of its giant pharmaceutical companies, of bullying developing countries into not using the measures in the Doha declaration and the EU of standing by and doing nothing. Doha technically allows poor countries to buy cheap copies of desperately needed drugs, but the US is accused of trying to prevent countries such as Thailand and India, which have manufacturing capacity, [from] making and selling cheap generic versions so as to preserve the monopolies of the drug giants. "Rich countries have broken the spirit of the Doha declaration," said Celine Charveriat, head of Oxfam's Make Trade Fair campaign. "The declaration said the right things but needed political action to work and that hasn't happened. In fact, we've actually gone backwards. Many people are dying or suffering needlessly." The US has pursued its own free trade agreements with developing countries, tying them into much tighter observance of patent rights than anticipated at Doha. "The USA has also pressured countries for greater patent protection through threats of trade sanctions," the report says.
Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.